SHC Stock Overview
Engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Sotera Health Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.33 |
| 52 Week High | US$17.44 |
| 52 Week Low | US$10.71 |
| Beta | 1.96 |
| 1 Month Change | 3.98% |
| 3 Month Change | -20.80% |
| 1 Year Change | -19.84% |
| 3 Year Change | -42.39% |
| 5 Year Change | n/a |
| Change since IPO | -46.89% |
Recent News & Updates
Recent updates
Here's Why Sotera Health (NASDAQ:SHC) Has A Meaningful Debt Burden
Dec 05
Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable
Sep 02Sotera Health (NASDAQ:SHC) Takes On Some Risk With Its Use Of Debt
Jun 25Sotera Health Company (NASDAQ:SHC) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 30The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%
Mar 21Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models
Mar 01McIntyre Partnerships - Sotera Health Company: A Notable Outlier At A Discount
Feb 08Is Sotera Health (NASDAQ:SHC) A Risky Investment?
Feb 06Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump
Dec 28Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price
Dec 11An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued
Sep 10Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate
Jun 05Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?
Feb 13Market Participants Recognise Sotera Health Company's (NASDAQ:SHC) Earnings Pushing Shares 29% Higher
Nov 24Sotera Health plunges 20% after jury awards $363M against its Sterigenics unit
Sep 19Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 49%?
Sep 08Shareholder Returns
| SHC | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 2.6% | -2.1% | -2.7% |
| 1Y | -19.8% | -5.5% | 23.4% |
Return vs Industry: SHC underperformed the US Life Sciences industry which returned -5.5% over the past year.
Return vs Market: SHC underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| SHC volatility | |
|---|---|
| SHC Average Weekly Movement | 4.5% |
| Life Sciences Industry Average Movement | 9.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SHC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SHC's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3,000 | Michael Petras | soterahealth.com |
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.
Sotera Health Company Fundamentals Summary
| SHC fundamental statistics | |
|---|---|
| Market cap | US$3.75b |
| Earnings (TTM) | US$70.49m |
| Revenue (TTM) | US$1.12b |
53.6x
P/E Ratio3.4x
P/S RatioIs SHC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SHC income statement (TTM) | |
|---|---|
| Revenue | US$1.12b |
| Cost of Revenue | US$502.46m |
| Gross Profit | US$618.01m |
| Other Expenses | US$547.52m |
| Earnings | US$70.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.25 |
| Gross Margin | 55.16% |
| Net Profit Margin | 6.29% |
| Debt/Equity Ratio | 473.4% |
How did SHC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 03:47 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sotera Health Company is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Polark | Baird |
| Luke Sergott | Barclays |
| Patrick Donnelly | Citigroup Inc |